OBJECTIVES:  To estimate costs of care for patients with chronic kidney disease (CKD) from an insurance company (IC) of a state subsidized in Colombia. METHODS: Patients with CKD were identified from a cardiovascular risk management program of an IC. Outpatient and inpatient costs were estimated from the ambulatory and hospitalization financial records of 2015 and from the health systems perspective. Medians and interquartile ranges were calculated and two groups of patients were defined based on the reported total cost (TC). Low cost: TC <75 percentile + 1.5 IQR and high cost: TC> 75th percentile + 1.5 IQR. Results were classified by stages of disease and converted to US dollars 2015. RESULTS:  Out of 61,611 patients affiliated to the program, 22.4% (13,816) were found to have CKD. In the defined low-cost group of patients, median hospitalization costs (MHC) and median outpatient costs (MOC) were as the following: stage 3a: US$720.1 (IQR US$1819.3), US$128.4 (IQR US$248.2); stage 3b: US$895.2 (IQR US$2060.6), US$135.7 (IQR US$264.0); stage 4: US$1074.2 (IQR US$2790), US$182.1 (IQR US$401.8); stage 5: US$2148.4 (IQR $2856.9), US$ 362.4 (IQR US$2226.7). In high cost group of patients, MHC and MOC were: stage 3a: US$12346.6 (IQR US$7704.2), US$5051.8 (IQR US$6158.4); stage 3b: US$12295.9 (IQR US$6486.1), US$3645.6 (IQR US$5282.8); stage 4: US$13014.7 (IQR US$12305.0), US$4850.9 (IQR US$8802.9); stage 5: US$11814.3 (IQR $10064.3), US$18869.2 (IQR US$6868). CONCLUSIONS: Among low cost patients, MHC stage 5 was 2.9 times higher than stage 3a and twice as high as stage 4. For high cost patients, stage 5 MOC was 3.7 times higher than stage 3a.